CY1112561T1 - Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης - Google Patents
Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινηςInfo
- Publication number
- CY1112561T1 CY1112561T1 CY20121100179T CY121100179T CY1112561T1 CY 1112561 T1 CY1112561 T1 CY 1112561T1 CY 20121100179 T CY20121100179 T CY 20121100179T CY 121100179 T CY121100179 T CY 121100179T CY 1112561 T1 CY1112561 T1 CY 1112561T1
- Authority
- CY
- Cyprus
- Prior art keywords
- eye
- vitreous
- plasmin
- reduce
- color
- Prior art date
Links
- 229940012957 plasmin Drugs 0.000 title abstract 3
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 108010088842 Fibrinolysin Proteins 0.000 abstract 2
- 101100045536 Arabidopsis thaliana TFCD gene Proteins 0.000 abstract 1
- 101100045541 Homo sapiens TBCD gene Proteins 0.000 abstract 1
- 208000007135 Retinal Neovascularization Diseases 0.000 abstract 1
- PLGPSDNOLCVGSS-UHFFFAOYSA-N Tetraphenylcyclopentadienone Chemical compound O=C1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 PLGPSDNOLCVGSS-UHFFFAOYSA-N 0.000 abstract 1
- 102100030290 Tubulin-specific chaperone D Human genes 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000005243 fluidization Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 108010015052 miniplasmin Proteins 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 208000000318 vitreous detachment Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02019—Chondroitin B lyase (4.2.2.19)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Insulating Materials (AREA)
Abstract
Μια μέθοδος για την θεραπευτική αντιμετώπιση ή αποτροπή μιας διαταραχής, ή μιας επιπλοκής μιας διαταραχής του οφθαλμού ενός υποκειμένου, που περιέχει την επαφή ενός υαλοειδούς και/ή υδατοειδούς υγρού με τη σύνθεση που περιέχει μια κόλουρη μορφή πλασμίνης, που περιέχει μια καταλυτική περιοχή πλασμίνης (ΤΡCD). Η ΤPCD περιλαμβάνει, χωρίς να περιορίζεται σε αυτά, μινιπλασμίνη, μικροπλασμίνη και παράγωγα και παραλλαγές αυτών. Οι μέθοδοι της εφεύρεσης μπορούν να χρησιμοποιηθούν για την μείωση του ιξώδους του υαλοειδούς, την υγροποίηση του υαλοειδούς, την πρόκληση οπίσθιας αποκόλλησης του υαλοειδούς, την μείωση του αιμορραγικού αίματος από τον οφθαλμό, τον καθαρισμό και την μείωση των τοξικών υλικών από τον οφθαλμό, τον καθαρισμό και την μείωση των ενδοοφθαλμικών ξένων ουσιών από τον οφθαλμό, την αύξηση της διάχυσης μιας σύνθεσης που χορηγείται στον οφθαλμό, την μείωση της επιαμφιβληστροειδικής νεοαγγείωσης και κάθε συνδυασμούς αυτών. Η μέθοδος μπορεί να χρησιμοποιηθεί με την απουσία της, ή ως συμπλήρωμα της υαλοειδεκτομής.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0228409.9A GB0228409D0 (en) | 2002-12-06 | 2002-12-06 | Pharmacological vitreolysis |
EP03812818A EP1581254B1 (en) | 2002-12-06 | 2003-12-05 | Pharmacological vitreolysis using truncated plasmin |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112561T1 true CY1112561T1 (el) | 2015-11-04 |
Family
ID=9949140
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100179T CY1112561T1 (el) | 2002-12-06 | 2012-02-21 | Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης |
CY2013033C CY2013033I2 (el) | 2002-12-06 | 2013-08-23 | Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2013033C CY2013033I2 (el) | 2002-12-06 | 2013-08-23 | Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης |
Country Status (25)
Country | Link |
---|---|
US (11) | US7547435B2 (el) |
EP (3) | EP2327416B1 (el) |
JP (4) | JP5426063B2 (el) |
CN (1) | CN100577202C (el) |
AT (1) | ATE534400T1 (el) |
AU (1) | AU2003300821C1 (el) |
BE (1) | BE2013C055I2 (el) |
BR (2) | BR0317033A (el) |
CA (1) | CA2508606C (el) |
CY (2) | CY1112561T1 (el) |
DK (1) | DK1581254T3 (el) |
ES (2) | ES2731625T3 (el) |
FR (1) | FR13C0052I2 (el) |
GB (1) | GB0228409D0 (el) |
HK (1) | HK1082419A1 (el) |
HU (1) | HUS1300040I1 (el) |
IL (3) | IL169008A (el) |
LU (1) | LU92273I2 (el) |
MX (1) | MXPA05006038A (el) |
NO (4) | NO333837B1 (el) |
NZ (1) | NZ541075A (el) |
PT (2) | PT2327416T (el) |
SI (1) | SI1581254T1 (el) |
WO (1) | WO2004052228A2 (el) |
ZA (1) | ZA200505193B (el) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7152975B2 (en) * | 2000-11-10 | 2006-12-26 | Cooper Vision, Inc. | Junctionless ophthalmic lenses and methods for making same |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
MXPA06012236A (es) | 2004-04-22 | 2007-01-31 | Talecris Biotherapeutics Inc | Plasmina modificada en forma recombinante. |
JP4796787B2 (ja) | 2005-04-28 | 2011-10-19 | 富士フイルム株式会社 | ラビリンチュラ類への遺伝子導入法 |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
WO2007005856A1 (en) * | 2005-06-30 | 2007-01-11 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment |
WO2007047874A2 (en) * | 2005-10-20 | 2007-04-26 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
US20070134231A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes and compositions thereof |
US20070134230A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes |
US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
US20070212358A1 (en) * | 2006-03-10 | 2007-09-13 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
EP2012826B1 (en) * | 2006-05-04 | 2016-04-13 | Fovea Pharmaceuticals | Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases |
AU2008331545B2 (en) | 2007-11-29 | 2014-01-16 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
US20110142819A1 (en) * | 2008-01-22 | 2011-06-16 | Omnio Healer Ab | Method of improving would healing |
ES2441966T3 (es) * | 2008-03-31 | 2014-02-07 | Scarcell Therapeutics | Procedimiento para el tratamiento cosmético del fotoenvejecimiento de la piel |
RU2497948C2 (ru) * | 2008-06-04 | 2013-11-10 | Тэйлкрис Байотерапьютикс, Инк. | Композиция, способ и набор для получения плазмина |
ES2552337T3 (es) | 2009-03-03 | 2015-11-27 | Grifols Therapeutics Inc. | Procedimientos para la preparación de plasminógeno |
US8858924B2 (en) * | 2009-03-26 | 2014-10-14 | Warsaw Orthopedic, Inc. | Compositions and methods for treatment of hemorrhage |
CN102482338B (zh) | 2009-07-10 | 2016-09-28 | 斯路姆基因公司 | 纤溶酶原和纤溶酶的变体 |
ES2534911T3 (es) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
US20110135626A1 (en) * | 2009-12-08 | 2011-06-09 | Alcon Research, Ltd. | Localized Chemical Lysis of Ocular Tissue |
MX337248B (es) | 2011-01-05 | 2016-02-19 | Thrombogenics Nv | Variantes de plasminogeno y plasmina. |
US20120329873A1 (en) * | 2011-06-17 | 2012-12-27 | Li yong-xin | D-serine for the treatment of visual system disorders |
WO2013024074A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
RU2484795C2 (ru) * | 2011-08-18 | 2013-06-20 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Способ индукции задней отслойки стекловидного тела с помощью миниплазмина |
ES2628321T3 (es) | 2011-12-01 | 2017-08-02 | Thrombogenics N.V. | Mejora del resultado de una trabeculectomía |
CN103205410B (zh) * | 2012-01-13 | 2018-03-06 | 蔺莹莹 | 重组微纤维蛋白溶酶及其制备方法和应用 |
CA2871528A1 (en) | 2012-04-24 | 2013-10-31 | Thrombogenics N.V. | Anti-pdgf-c antibodies |
EP2968476B1 (en) | 2013-03-14 | 2021-05-05 | Wayne State University | A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016054079A1 (en) | 2014-09-29 | 2016-04-07 | Zyomed Corp. | Systems and methods for blood glucose and other analyte detection and measurement using collision computing |
FR3034992A1 (fr) | 2015-04-15 | 2016-10-21 | Arcadophta | Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention |
WO2017101867A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
EP3395354B1 (en) * | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
JP2019500426A (ja) * | 2015-12-18 | 2019-01-10 | タレンゲン インターナショナル リミティッドTalengen International Limited | 糖尿病網膜症を予防または治療するための方法 |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
RU2619991C1 (ru) * | 2016-02-18 | 2017-05-22 | Павел Владимирович Лыскин | Способ лечения витреомакулярного тракционного синдрома |
WO2017153567A1 (en) | 2016-03-10 | 2017-09-14 | Thrombogenics Nv | Posterior ocular fibrosis inhibition by antagonizing placental growth factor |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
TW201822803A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種抑制胰島β細胞凋亡的方法 |
EP3604497A4 (en) | 2017-03-28 | 2020-12-23 | Morinaga Milk Industry Co., Ltd. | NEW BACTERIA OF THE GENUS BIFIDOBACTERIUM |
RU2674926C1 (ru) * | 2018-02-01 | 2018-12-13 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. | Способ оценки эффективности витреолизиса помутнений стекловидного тела |
CN110361242B (zh) * | 2019-08-14 | 2022-01-18 | 武汉赛维尔生物科技有限公司 | 一种用于眼球组织的固定液以及眼球组织制片的预处理方法 |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US658972A (en) * | 1900-04-09 | 1900-10-02 | Interchangeable Brake Beam Company | Brake-beam. |
US2624691A (en) * | 1946-04-22 | 1953-01-06 | Parke Davis & Co | Fibrinolysin derived from blood and methods of obtaining the same |
DK98833C (da) | 1961-04-25 | 1964-05-25 | Novo Terapeutisk Labor As | Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger. |
US3234106A (en) * | 1962-12-03 | 1966-02-08 | Cutter Lab | Soluble, purified profibrinolysin and fibrinolysin and method of producing same |
US3950513A (en) * | 1965-12-03 | 1976-04-13 | Novo Terapeutisk Laboratorium A/S | Process of stabilizing therapeutically useful plasmin solutions |
IT1194135B (it) * | 1981-01-05 | 1988-09-14 | Novo Industri As | Composizioni di plasmina stabilizzata e metodo per la loro preparazione |
GB8504025D0 (en) | 1985-02-16 | 1985-03-20 | Biopharm Ltd | Hyaluronidase |
US4774087A (en) | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
US5288485A (en) * | 1989-08-31 | 1994-02-22 | Kao Corporation | Vasodilating agent |
ZA912770B (en) | 1990-04-16 | 1992-01-29 | Bethesda Eye Inst | Enzymatic disinsertion of vitreous body |
US5288489A (en) * | 1991-08-28 | 1994-02-22 | Orion Therapeutic Systems, Inc. | Fibrinolysis and fibrinogenolysis treatment |
AU4661493A (en) * | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
US5304118A (en) * | 1992-12-16 | 1994-04-19 | Trese Michael T | Method for performing a vitrectomy on an eye |
US5866120A (en) | 1995-11-22 | 1999-02-02 | Advanced Corneal Systems, Inc. | Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase |
US6610292B2 (en) * | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
US5973779A (en) | 1996-03-29 | 1999-10-26 | Ansari; Rafat R. | Fiber-optic imaging probe |
US6207066B1 (en) * | 1996-07-23 | 2001-03-27 | Nuvue Technologies, L.L.C. | Method for purification of a blood component |
US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US5722428A (en) * | 1996-10-29 | 1998-03-03 | Washington University | Method for producing a posterior vitreous detachment |
US6596725B2 (en) * | 1997-02-10 | 2003-07-22 | Inspire Pharmaceuticals, Inc. | Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema |
DE69836858T2 (de) | 1997-05-22 | 2007-09-06 | Ista Pharmaceuticals, Inc., La Jolla | Verwendung von hyaluronidase zur herstellung eines augenpräparats zur glasskörperverflüssigung bei der behandlung von augenerkrankungen |
CN1322126C (zh) | 1998-02-04 | 2007-06-20 | 思罗姆-X股份有限公司 | 免疫原性降低和/或清除率降低的葡激酶衍生物的鉴定、生产和应用 |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
US20040081643A1 (en) * | 1999-03-09 | 2004-04-29 | Peyman Gholam A. | Process for inhibiting vascular proliferation in the eye |
US6733750B1 (en) * | 1999-03-09 | 2004-05-11 | Minu, L.L.C. | Process and composition for inducing posterior vitreous detachment |
US6899877B2 (en) * | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
US6585972B2 (en) * | 1999-03-09 | 2003-07-01 | Gholam A. Peyman | Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
AU1057901A (en) | 1999-11-10 | 2001-06-06 | Center For Advanced Science And Technology Incubation, Ltd. | Method of preparing cell fraction containing hemangioblasts |
US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
EP1297016B1 (en) * | 2000-05-12 | 2006-03-22 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
DE60131450T2 (de) * | 2000-12-21 | 2008-10-16 | Thrombogenics N.V. | Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle |
US20020139378A1 (en) * | 2001-03-28 | 2002-10-03 | Trese Michael T. | Method for creating a separation of posterior cortical vitreous from the retina of the eye |
FI20011132A0 (fi) | 2001-05-30 | 2001-05-30 | Innovationsagentur | Markkeri hematopoieettisten kantasolujen tunnistamiseen |
US7776026B2 (en) * | 2002-02-06 | 2010-08-17 | Nuvue Technologies, Inc. | Method for vitreous liquefaction |
US6787135B2 (en) * | 2002-03-13 | 2004-09-07 | William Beaumont Hospital | Modification of vitreal matrix metalloproteinase activity |
US20040235115A1 (en) * | 2002-11-18 | 2004-11-25 | Reed Guy L. | Compositions and methods for treating thrombotic disorders |
GB0228409D0 (en) * | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
US20070212358A1 (en) * | 2006-03-10 | 2007-09-13 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
-
2002
- 2002-12-06 GB GBGB0228409.9A patent/GB0228409D0/en not_active Ceased
-
2003
- 2003-12-05 CA CA2508606A patent/CA2508606C/en not_active Expired - Lifetime
- 2003-12-05 BR BR0317033-0A patent/BR0317033A/pt unknown
- 2003-12-05 ES ES11152414T patent/ES2731625T3/es not_active Expired - Lifetime
- 2003-12-05 EP EP11152414.6A patent/EP2327416B1/en not_active Expired - Lifetime
- 2003-12-05 MX MXPA05006038A patent/MXPA05006038A/es active IP Right Grant
- 2003-12-05 EP EP11152403.9A patent/EP2327415B1/en not_active Expired - Lifetime
- 2003-12-05 BR BRPI0310144A patent/BRPI0310144A8/pt not_active Application Discontinuation
- 2003-12-05 CN CN200380108773A patent/CN100577202C/zh not_active Expired - Fee Related
- 2003-12-05 EP EP03812818A patent/EP1581254B1/en not_active Expired - Lifetime
- 2003-12-05 DK DK03812818.7T patent/DK1581254T3/da active
- 2003-12-05 ES ES03812818T patent/ES2377965T3/es not_active Expired - Lifetime
- 2003-12-05 WO PCT/US2003/038714 patent/WO2004052228A2/en active Application Filing
- 2003-12-05 PT PT11152414T patent/PT2327416T/pt unknown
- 2003-12-05 AT AT03812818T patent/ATE534400T1/de active
- 2003-12-05 PT PT03812818T patent/PT1581254E/pt unknown
- 2003-12-05 US US10/729,475 patent/US7547435B2/en not_active Expired - Lifetime
- 2003-12-05 NZ NZ541075A patent/NZ541075A/en not_active IP Right Cessation
- 2003-12-05 JP JP2004559328A patent/JP5426063B2/ja not_active Expired - Fee Related
- 2003-12-05 AU AU2003300821A patent/AU2003300821C1/en not_active Expired
- 2003-12-05 SI SI200332111T patent/SI1581254T1/sl unknown
-
2005
- 2005-06-05 IL IL169008A patent/IL169008A/en active Protection Beyond IP Right Term
- 2005-06-17 NO NO20052988A patent/NO333837B1/no not_active IP Right Cessation
- 2005-06-20 ZA ZA200505193A patent/ZA200505193B/xx unknown
-
2006
- 2006-03-28 HK HK06103894.5A patent/HK1082419A1/xx not_active IP Right Cessation
-
2007
- 2007-04-11 US US11/786,250 patent/US7803368B2/en not_active Expired - Fee Related
- 2007-04-11 US US11/786,354 patent/US7914783B2/en not_active Expired - Fee Related
-
2008
- 2008-06-05 US US12/156,907 patent/US8460655B2/en active Active
- 2008-06-05 US US12/156,911 patent/US7867489B2/en not_active Expired - Fee Related
-
2009
- 2009-12-20 IL IL202851A patent/IL202851A/en active Protection Beyond IP Right Term
-
2010
- 2010-06-04 JP JP2010128670A patent/JP5451533B2/ja not_active Expired - Fee Related
- 2010-11-22 US US12/951,787 patent/US8383105B2/en not_active Expired - Lifetime
-
2011
- 2011-04-29 US US13/097,985 patent/US8747842B2/en not_active Expired - Fee Related
- 2011-06-29 IL IL213838A patent/IL213838A0/en active IP Right Grant
-
2012
- 2012-02-21 CY CY20121100179T patent/CY1112561T1/el unknown
- 2012-10-12 NO NO20121170A patent/NO20121170A1/no not_active Application Discontinuation
- 2012-10-12 NO NO20121169A patent/NO343759B1/no not_active IP Right Cessation
- 2012-11-29 US US13/689,025 patent/US8834869B2/en not_active Expired - Fee Related
- 2012-11-30 US US13/690,427 patent/US20130202613A1/en not_active Abandoned
-
2013
- 2013-03-14 US US13/827,986 patent/US9186394B2/en not_active Expired - Fee Related
- 2013-08-01 JP JP2013160571A patent/JP5739487B2/ja not_active Expired - Fee Related
- 2013-08-15 HU HUS1300040C patent/HUS1300040I1/hu unknown
- 2013-08-23 CY CY2013033C patent/CY2013033I2/el unknown
- 2013-08-29 BE BE2013C055C patent/BE2013C055I2/fr unknown
- 2013-08-29 FR FR13C0052C patent/FR13C0052I2/fr active Active
- 2013-08-29 LU LU92273C patent/LU92273I2/fr unknown
- 2013-11-19 NO NO2013016C patent/NO2013016I2/no unknown
-
2014
- 2014-06-27 US US14/318,232 patent/US9770494B2/en not_active Expired - Lifetime
-
2015
- 2015-03-24 JP JP2015060570A patent/JP5996026B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112561T1 (el) | Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης | |
EA200700109A1 (ru) | Способы лечения офтальмологических состояний (варианты) | |
DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
DE60119534D1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
DK1776349T3 (da) | 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE) | |
BR0007595A (pt) | 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina | |
ATE295829T1 (de) | Verwendung von biologisch aktivem glas zum schneiden von biologisch aktivem glas | |
NO990522L (no) | Anvendelse av <beta>-ark mimetika som protease- og kinaseinhibatorer av transkripsjonsfaktorer | |
AR036199A1 (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas | |
BR0210013A (pt) | Gel oftálmico de pirenzepina | |
BR9914128A (pt) | Composições antibióticas para tratamento do olho, ouvido e nariz | |
PE20020144A1 (es) | Derivados de pleuromutilinas como agentes antibacterianos | |
ATE288274T1 (de) | Ophatlmologische zusammenssetzung | |
DE60317098D1 (de) | Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten | |
CY1106409T1 (el) | Παραγωγα κινολινης | |
NO20051013L (no) | N-ureidoalkyl-piperidiner som modulerende forbindelser av kjemokinreseptor-aktivitet | |
PT1169026E (pt) | Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular | |
BR9901566A (pt) | Análogos cis-delta4 de prostaglandinas como hipotensores oculares |